Establishment of a TRPV2 knockout human embryonic stem cell line (WAe009-A-1Y) using episomal vector-based CRISPR/Cas9
We established a TRPV2-knockout human embryonic stem cell line (WAe009-A-1Y) using a non-integrating episomal CRISPR/Cas9 system. This cell line exhibits an 8-nucleotide frameshift deletion in TRPV2 exon 2, confirmed pluripotency (97.6 % SSEA4+ cells, trilineage differentiation), and a normal female karyotype (46, XX) at passage 30. TRPV2 ablation was validated in differentiated cardiomyocytes, showing >90 % mRNA reduction and absent protein expression. No off-target edits or mycoplasma contamination were detected. This cell resource (STR-authenticated, off-target-free) provides a robust in vitro model to study the biological function of TRPV2 in cardiac mechanotransduction and disease.
Authors
- Xujie Liu (ORCID: https://orcid.org/0000-0001-8713-4287)
- Rui Bai (ORCID: https://orcid.org/0000-0003-4982-7562)
- Xiaoyan Gu (ORCID: https://orcid.org/0000-0002-9822-3960)
- Siyao Zhang (ORCID: https://orcid.org/0009-0006-0027-8776)
- Yi You
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Soochow University (CN)
- Beijing Anzhen Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
- Fu Wai Hospital (CN)
Publication Details
- Journal
- Stem Cell Research
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1016/j.scr.2025.103744
- Citations
- 1
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Natural Science Foundation of China